Company / Revenue
Travere Therapeutics, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$490.7M
FY2025
5-year range
$109.5M / $490.7M
FY2021-FY2025
Trend
+110.5%
vs FY2024
Sector context
#66 of 155
Health Care
What the data says
At $491M, Travere Therapeutics, Inc.'s revenue ranks #66 of 155 in the Health Care sector. Revenue has increased for 3 consecutive years, from $109M in FY2022 to $491M in FY2025.
Based on SEC 10-K filings.
$491M in FY2025 with a 5-year CAGR of +24.5%.
Improved from $145M to $491M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +64.9%
- 5-Year CAGR
- +24.5%
- 10-Year CAGR
- -
Sector benchmark
#66 of 155 in Health CareTop 43% of 155This company $490.7M Sector average $4.5B
▼
-89.0% below sector average
Key checks
Key Insights
- Travere Therapeutics, Inc.'s revenue has grown for 3 consecutive years.
- 5-year CAGR of +24.5%, indicating consistent growth.
- In FY2025, revenue increased 110.5% year-over-year.
- Ranks #66 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $490.7M | +110.5% |
| FY2024 | $233.2M | +60.5% |
| FY2023 | $145.2M | +32.7% |
| FY2022 | $109.5M | -37.6% |
| FY2021 | $175.3M | +6.8% |
| FY2020 | $164.2M | +6.0% |
| FY2019 | $154.9M | +16.0% |
| FY2018 | $133.6M | +33.7% |
| FY2017 | $99.9M | +254.2% |
| FY2016 | $28.2M | -71.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026